Secukinumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Secukinumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target IL17A
Clinical data
Legal status Investigational
Identifiers
CAS number  YesY
ATC code L04AC10
Synonyms AIN457
Chemical data
Formula C6584H10134N1754O2042S44 
Mol. mass 147.94 kDa
 YesY (what is this?)  (verify)

Secukinumab is a human monoclonal antibody designed for the treatments of uveitis, rheumatoid arthritis, and psoriasis. It targets member A from the cytokine family of interleukin 17.[1][2]

Secukinumab was developed by Novartis Pharma AG and has completed Phase II clinical trials for plaque psoriasis in 2011.[3]

As of March 2014, Secukinumab entered Phase IIIb clinical trials comparing efficacy against Amgen's Enbrel.[4]

It is also in a phase II clinical trial for Multiple Sclerosis [5] as it has exhibited efficacy in treating experimental autoimmune encephalomyelitis (EAE), an animal model of MS.

CAS registry numbers[edit]

  • 875356-43-7 (heavy chain)
  • 875356-44-8 (light chain)

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Secukinumab". American Medical Association. 
  2. ^
    1. REDIRECT Template:Cite pmid
  3. ^ Papp K.A. et al. 'Secukinumab efficacy and safety preliminary results from a phase II subcutaneous dose-ranging study in the treatment of moderate-to-severe plaque psoriasis.' Presented at: 20th Congress of the European Academy of Dermatology and Venereology; 20-24 October, 2011; Lisbon, Portugal.
  4. ^ "Novartis announces start of new secukinumab (AIN457) versus Stelara® (ustekinumab) phase IIIb head-to-head psoriasis study at AAD 2014". Novartis AG. 
  5. ^ http://clinicaltrials.gov/show/NCT01874340